You may have heard that now is the time to buy risk. In fact, BlackRock chief investment officer Bob Doll told CNBC viewers in October that "risk assets will continue to outperform safe assets."
Burt White, chief investment officer at LPL Financial,
took that message one step further. He told CNN that it's
time to "Sell the dollar and buy risk. It's a crowded trade,
but a good one."
So what exactly is a "risk asset," and is it really a
good trade if it's so crowded? I'm glad you asked.
Profile of a risk asset
As it turns out, a "risk asset" isn't nearly
as risky as it sounds. It's a general term that refers to
stocks and bonds generally, whereas a "safe asset" is
Treasuries or cash. Further, when Doll was talking about
"risk assets," he was actually referring to blue-chip stocks
such as
Johnson & Johnson (NYSE: JNJ),
Intel (Nasdaq: INTC), and
CSX (NYSE: CSX).
While those are good companies no doubt, I actually
believe there's room in your portfolio today for slightly
more "risk" ... and I'd like to help you put it there. But
before we can do that, we need to be sure we're working from
the same assumptions.
Make yours like mine
A recent article in
The New York Timesrevealed a startling new reality.
Namely, Mexicans who came to the United States to work are no
longer sending money home to support their families. Instead,
their families are now sending money north to support them!
Leaving aside the politics of labor migration, this is
an incredible development. It means that our country, one
that has attracted immigrants in search of opportunity for
hundreds of years, is now struggling to create those
opportunities. That, however, is what's bound to happen as an
economy matures.
Combine that with the reality of massive and growing
U.S. debts and you get a rather grim outlook for the U.S.
economy.
Here's what we can do
To solve for this, I agree with experts I
cited above who advise us to favor stocks and eschew cash and
Treasuries. But I'll do them one better and advise that we
should tilt our stock exposure
awayfrom the United States.
This does slightly raise your risk of near-term
volatility given currency issues in places like Mexico,
corruption issues in places like Brazil, and governance
issues in places like China, but it doesn't mean you can't
buy blue-chip-type companies. These would be names such as
America Movil (NYSE: AMX),
Canadian National Railway (NYSE: CNI),
Novartis (NYSE: NVS), and even something like
Dr. Reddy's Laboratories (NYSE: RDY). These
are all conservatively run companies with modest valuations
in defensive industries.
In fact, Dr. Reddy's is one of the companies we're slated
to meet with during our upcoming
Motley Fool Global Gainsresearch trip to India. And
while it's quite a bit smaller and pricier than the classic
blue chip, we like its opportunity to bring needed generic
and other pharmaceuticals to the world's emerging markets.
A word of warning
Remember, however, that these "risk" trades
are crowded trades today. In fact, emerging-markets stocks
have been among the most popular asset classes with investors
this year (for more on that, see
here). But that's why you need the added intelligence of
the research we'll be providing in real time from the field
in India.
The good news for you is that that research is free,
and that we'll email it straight to you if you tell us where
to send it.
Click hereto do just that.
© 2009 UCLICK L.L.C.